Saudi Journal of Kidney Diseases and Transplantation

BRIEF COMMUNICATION
Year
: 2014  |  Volume : 25  |  Issue : 4  |  Page : 819--822

Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation


Himanshu V Patel1, Vivek B Kute1, Aruna V Vanikar2, Pankaj R Shah1, Manoj R Gumber1, Divyesh P Engineer1, Hargovind L Trivedi1 
1 Department of Nephrology and Clinical Transplantation, Laboratory Medicine, Transfusion Services and Immunohematology, Institute of Kidney Diseases and Research Center, Dr. H. L. Trivedi Institute of Transplantation Sciences, Ahmedabad, India
2 Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, Institute of Kidney Diseases and Research Center, Dr. H. L. Trivedi Institute of Transplantation Sciences, Ahmedabad, India

Correspondence Address:
Himanshu V Patel
Department of Nephrology and Clinical Transplantation, Institute of Kidney Diseases and Research Centre, Dr. H. L. Trivedi Institute of Transplantation, Civil Hospital Campus, Asarwa, Ahmedabad - 380 016, Gujarat
India

We conducted a single-center prospective double-arm open-labeled study on kidney transplant patients from 2010 to 2011 to evaluate the efficacy of induction therapy using low, single-dose rabbit-antithymocyte globulin (r-ATG), 1.5 mg/kg on Day 0 (n = 80, 60 males, mean age 35.9 years), versus basiliximab (Interleukin-2 blocker) 20 mg on Days 0 and 4 (n = 20, 12 males, mean age 45.1 years) on renal allograft function in terms of serum creatinine (SCr), rejec­tion and infection episodes and patient/graft survival and cost. Demographic and post-transplant follow-up including immunosuppression was similar in both groups. In the r-ATG group, donors were unrelated (spouse, n = 25), deceased (n = 31) and parents/siblings (others), with a mean HLA match of 1.58. Donors in the basiliximab group were living unrelated (spouse, n = 15) and deceased (n = 5), with a mean HLA match of 1.56. No patient/graft was lost in the r-ATG group over a mean of one year follow-up, and the mean SCr was 1.28 mg/dL with 7.5% acute rejection (AR) episodes; infections were also not observed. In the basiliximab group, over the same period of follow-up, there was 95% death-censored graft survival, and the mean SCr was 1.23 mg/dL with 10% AR episodes. One patient died due to bacterial pneumonia and one succumbed to coronary artery disease; one graft was lost due to uncontrolled acute humoral and cellular rejection. The cost of r-ATG and basiliximab were $600 and $2500, respectively. We conclude that induction immunosuppressive therapy with a low-dose r-ATG may be a better option as compared with basiliximab in terms of graft function, survival and cost benefit in kidney transplant patients.


How to cite this article:
Patel HV, Kute VB, Vanikar AV, Shah PR, Gumber MR, Engineer DP, Trivedi HL. Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation.Saudi J Kidney Dis Transpl 2014;25:819-822


How to cite this URL:
Patel HV, Kute VB, Vanikar AV, Shah PR, Gumber MR, Engineer DP, Trivedi HL. Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation. Saudi J Kidney Dis Transpl [serial online] 2014 [cited 2022 Jan 17 ];25:819-822
Available from: https://www.sjkdt.org/article.asp?issn=1319-2442;year=2014;volume=25;issue=4;spage=819;epage=822;aulast=Patel;type=0